 | Up a level |
Journal Article
Borchmann, S., Hude, I., Sasse, S., Broeckelmann, P., von Tresckow, B., Momotow, J. and Engert, A. (2017). Leukocyte and eosinophil count at baseline predict outcome in relapsed or refractory classical Hodgkin lymphoma patients treated with immune checkpoint inhibitors. Oncol. Res. Treat., 40. S. 142 - 144. BASEL: KARGER. ISSN 2296-5262
Hude, I., Sasse, S., Broeckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A. and Borchmann, S. (2017). BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION. Haematologica, 102. S. 460 - 461. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262
Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2022). Treatment of early stage favorable and unfavorable Hodgkin lymphoma. Onkologie, 28 (10). S. 879 - 889. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234
Sasse, S., Momotow, J. and Engert, A. (2020). Checkpoint inhibitors in Hodgkin lymphoma. Internist, 61 (7). S. 660 - 669. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289